{{Rsnum
|rsid = 28933999
|Gene = RYR1
|geno1 = (A;A)
|geno2 = (A;G)
|geno3 = (G;G)
|Orientation=plus
|ReferenceAllele=G
|MissenseAllele=A
|Chromosome=19
|position=38494565
|Gene_s=RYR1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Status=Merged
|Merged=118192163
}}{{omim
| id = 180901
| variant = 0011
| desc    = MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1
| rsnum   = 28933999
}}
{{ neighbor
| rsid = 28933998
| distance = 1
}}

{{PharmGKB
|RSID=rs28933999
|Name_s=p.R2163H
|Gene_s=RYR1
|Feature=
|Evidence=PubMed ID:19648156
|Annotation=Risk or phenotype-associated allele: A. Phenotype: Different RYR1 variants are associated with significant differences in in vitro contracture tests (IVCT) and creatine kinase (CK) phenotypes; more specifically, the variants p.R163C, p.R2163H (rs28933999 G to A), p.R2435H (rs28933396 G to A), and p.T4826I were significantly associated with a more severe form of each quantitative phenotype Study size: 450. Study population/ethnicity: Malignant hyperthermia -susceptible individuals (Caucasians).
|Drugs=
|Drug Classes=
|Diseases=Malignant Hyperthermia
|Curation Level=Curated
|PharmGKB Accession ID=PA165110373
}}

{{PharmGKB
|RSID=rs28933999
|Name_s=RYR1:ARG2163HIS
|Gene_s=RYR1
|Feature=
|Evidence=PubMed ID:10051009
|Annotation=This SNP has been associated with Malignant Hyperthermia Susceptibility with Central Core Disease.
|Drugs=
|Drug Classes=
|Diseases=Malignant Hyperthermia
|Curation Level=Curated
|PharmGKB Accession ID=PA162360059
}}